Last reviewed: July 11, 2026 Last updated: July 11, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Government-backed Medicare plans for adults aged 65 and older and those with disabilities are barred from covering weight-loss treatments, though the Biden administration has proposed to expand the coverage of anti-obesity drugs
Other conditions that may exclude GLP-1s like tirzepatide from your options
If approved, your annual cost will likely be $1,800 to $2,400
In India, the price differential between the off-patent and original brands may be small, given existing aggressive pricing, and so robust RWE studies could give a differentiating edge, especially for companies developing oral semaglutide where the existing market is less established
His story reflects the importance of consistent access to treatment